PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Blue Cross & Blue Shield of MississippiCommercial · Coverage · Medical Policy · MS · Rheumatology, Hematology, Nephrology +2 moreMedium impact

State and School Employees' Health Insurance Plan - Rituximab Non-Oncology

Effective date
Not stated in the notice
Identified
Jun 20, 2026

Summary

Riabni (rituximab-arrx), Ruxience (rituximab-pvvr), and Truxima (rituximab-abbs) may be considered medically necessary for listed non-oncologic indications when the criteria for that condition are met, including rheumatoid arthritis, ANCA-associated vasculitis, pemphigus, autoimmune hemolytic anemia, chronic graft versus host disease, immune thrombocytopenia, neuromyelitis optica spectrum disorder, systemic lupus erythematosus, thrombotic thrombocytopenic purpura, multiple sclerosis, membranous nephropathy, and refractory myasthenia gravis. The 11/01/2026 update added Riabni as medically necessary and added HCPCS code Q5123. The 06/15/2026 update revised the criteria for the listed conditions and added a prescriber and dosage requirement.

Get alerts when payers change rules like this one

We check Blue Cross & Blue Shield of Mississippi and other payers every day and email you when a change matches your specialty and state.

Get Blue Cross & Blue Shield of Mississippi alertsPolicy Monitoring is free. No card required.

What to do

Action · 9 steps
01Before billing Riabni (Q5123), Ruxience (Q5119), or Truxima (Q5115) for a non-oncologic indication, confirm the member meets the criteria for that diagnosis, and document it in the chart.
02Examples include the conventional-agent history for rheumatoid arthritis, the prior therapy and documented response for the other conditions, and hepatitis B screening with HBsAg and anti-HBc before treatment.
03If the screening is positive, hepatitis B therapy must have begun.
04The member must not be treated with another immunomodulatory agent such as a TNF inhibitor, JAK inhibitor, or IL inhibitor.
05The prescriber must be a specialist or have consulted one for the diagnosis, and the dose must be within program quantity limits or compendia-supported dosing.
06Initial approval lasts up to 12 months, and renewal requires documented clinical response.
07Stop billing Rituxan (J9312) for these members, because Rituxan is considered not medically necessary on all Blue Cross & Blue Shield of Mississippi formularies as other formulary alternatives are available.
08Rituxan Hycela is considered investigational for non-oncologic diagnoses.
09Services related to delivery or administration of a medication determined not medically necessary are also not medically necessary.

Codes mentioned

C9399Q5115Q5119Q5123G36.0M05.00M06.09M06.80M06.9M06.0AM31.30M31.31M31.7J9312

Original notice

State and School Employees' Health Insurance Plan - Rituximab Non-Oncology
bcbsms.com · Always check the source before changing claims.
View original ↗

Related policy hubs

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account